Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs SK Hynix (SKHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs SK Hynix — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while SK Hynix trades at $136.55 (market cap $771.50B). The key difference: SK Hynix is far larger — about 789.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and SK Hynix pays a 0.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SK Hynix for 12 Days on average.
| MRVI | SKHY | |
|---|---|---|
Market Cap | $977.37M | $771.50B |
Volume | 2,742,564 | 22,899,644 |
Sector | Health | Technology |
52-Week High | $9.00 | $198.63 |
52-Week Low | $2.83 | $126.79 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $1.08B | $721.62B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SKHY trades at $157.06, down 3.15% amid a sector-wide tech selloff driven by Fed rate hike concerns and competitive threats from Chinese chipmaker CXMT. The stock shows strong fundamentals with a P/E of 9.27, net income margin of 85.62%, and consistent earnings beats. Technical indicators are bearish with moving averages signaling selling pressure, though oscillators suggest potential oversold conditions. Recent news highlights AI memory demand growth but also increased competition risks.
Despite near-term volatility, SKHY maintains robust profitability and analyst consensus remains bullish with a $242 price target representing 54% upside. Key risks include Chinese competition and macroeconomic pressures, but the company's leadership in AI memory and strong financial metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About SK Hynix
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →
